Saniona (formerly known as Aniona ApS) is a clinical stage pharma company, developing therapies targeting various ion-channels for the treatment of central nervous system disorders.
[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”SANION.ST” api=”yf” style=”font-size: 15px”]
In 2013, Saniona entered partnership with Atlas Venture Inc. & transferred all rights of the active substances included in its Ataxia-program to a new company Ataxion Inc. in Boston where Saniona in turn received an ownership of Ataxion.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/aniona” connections=”true” suffix=””]
In 2009, Neurosearch entered a collaboration agreement with Janssen Pharmaceutical for the discovery development & commercialization of medicines treating CNS diseases. In 2015, Janssen terminate the entire agreement covering the GABAa5 program including the lead compound AN470. Saniona regains all rights to its GABAa5 program and the lead compound AN470.
In Jul 2018, Saniona, received a research milestone of ã 4mn from Boehringer Ingelheim. Saniona may receive up to ã90mn in milestone payments that include up to ã50mn upon the achievement of certain research, development and regulatory milestones and up to ã35mn in commercial milestone.